Prosecution Insights
Last updated: April 19, 2026
Application No. 18/274,630

TRIHETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Non-Final OA §112
Filed
Jul 27, 2023
Examiner
MOORE, SUSANNA
Art Unit
1624
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Apeiron Therapeutics Company Limited
OA Round
1 (Non-Final)
68%
Grant Probability
Favorable
1-2
OA Rounds
3y 0m
To Grant
99%
With Interview

Examiner Intelligence

Grants 68% — above average
68%
Career Allow Rate
842 granted / 1237 resolved
+8.1% vs TC avg
Strong +32% interview lift
Without
With
+32.2%
Interview Lift
resolved cases with interview
Typical timeline
3y 0m
Avg Prosecution
68 currently pending
Career history
1305
Total Applications
across all art units

Statute-Specific Performance

§101
1.4%
-38.6% vs TC avg
§103
18.6%
-21.4% vs TC avg
§102
17.3%
-22.7% vs TC avg
§112
36.6%
-3.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1237 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . This is the first action on the merits. Claims 3, 4, 6, 8, 10, 11, 13, 17, 19 and 20 are pending and under consideration. Election/Restrictions Applicant's election with traverse of Group (I) in the reply filed on December 27, 2025 is acknowledged. Group (I), drawn to compounds of formula IA, embraced by claims 1-11, 13 and 17-20 was elected by Applicant. The traversal is on the ground(s) that Groups (I) and (II) are sufficiently related such that an undue burden would not be present. This is not found persuasive because undue burden corresponds to only US applications and not 371 applications. Applicant has not pointed to any errors in the Examiner’s analysis of the classification of the different inventions. The requirement is still deemed proper and is therefore made FINAL. Applicant elected, with traverse, the following species: PNG media_image1.png 261 438 media_image1.png Greyscale PNG media_image2.png 312 445 media_image2.png Greyscale Applicant indicated claims 3, 4, 6, 8, 10, 11, 13, 17, 19 and 20 read on said species. Based on the search, the species election has been withdrawn. The application is entitled to rejoinder of the method claims that are commensurate in scopes with the allowable product claims and with the restriction requirement. Priority Receipt is acknowledged of certified copies of papers required by 37 CFR 1.55. Moreover, Applicant has provided translations of foreign priority documents 202110768196.9, with a filing date of July 7, 2021 and 202110151579.1, with a filing date of February 3, 2021. The present claims are afforded the priority date of February 3, 2021 based on the translation received by the office on December 27, 2025. Claim Objections Claims 3, 4, 8, 10 and 17 are objected to because of the following informalities: the term “independently” is used when only one variable is defined, see e.g., R1a in claim 1. This occurs throughout said claims. Appropriate correction is required. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claim 8 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. In claim 8, the definitions of the variables B and A2 are vague. The definition is broader than what is claimed in claim 3. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to SUSANNA MOORE whose telephone number is (571)272-9046. The examiner can normally be reached Monday - Friday, 10:00 am to 7:00 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jeffrey Murray can be reached on 571-272-9023. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SUSANNA MOORE/Primary Examiner, Art Unit 1624
Read full office action

Prosecution Timeline

Jul 27, 2023
Application Filed
Jan 24, 2026
Non-Final Rejection — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12600717
TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS
2y 5m to grant Granted Apr 14, 2026
Patent 12583868
JAK INHIBITORS AND METHODS FOR SYNTHESIZING AND USING THEREOF
2y 5m to grant Granted Mar 24, 2026
Patent 12570656
PURINE COMPOUNDS FOR TREATING DISORDERS
2y 5m to grant Granted Mar 10, 2026
Patent 12552810
CRYSTALLINE FORMS OF CFTR MODULATORS
2y 5m to grant Granted Feb 17, 2026
Patent 12552804
TRICYCLIC HETEROCYCLES AS FGFR INHIBITORS
2y 5m to grant Granted Feb 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

1-2
Expected OA Rounds
68%
Grant Probability
99%
With Interview (+32.2%)
3y 0m
Median Time to Grant
Low
PTA Risk
Based on 1237 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month